Enter multiple symbols separated by commas

Glaxo Says New Study Shows No Avandia Heart Risk

A new study of health insurance records of more than 400,000 U.S. diabetics found no higher risk of heart attacks with GlaxoSmithKline'spill Avandia when compared with other oral diabetes drugs, the drugmaker said in documents made public Thursday.

The study also showed no higher rate of coronary revascularization procedures, such as bypass surgery, in patients who took Avandia, the company said.

Glaxo funded the study, which was done by researchers at i3 Drug Safety, a division of health information company Ingenix.

The findings were included in a summary Glaxo provided to the Food and Drug Administration, which is holding an advisory panel meeting on Monday to evaluate Avandia's heart risks.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Pro predicts dramatic slowdown

    Dissecting this week's market activity, with Jim LaCamp, UBS; David Seaburg, Cowen and Company; CNBC's Sara Eisen and Bob Pisani.

  • In good standing

    What are the warning signs that your finances aren┬┐t in good shape? Personal Finance Correspondent Sharon Epperson discusses the vital signs of financial and fiscal fitness and what you can do to stay on track.

  • Uncorked

    Sparkling wines are growing in popularity. Food & Wine Magazine Executive Wine Editor Ray Isle shows which bottles stand up to the taste test and won't break the bank.